Targeting bacterial biofilm lynchpin prevents, treats recalcitrant biofilm-mediated infections

July 07, 2020

Chronic and recurrent bacterial diseases are treatment-resistant due to the ability of the pathogens to establish biofilms, which act as fortresses built of extracellular DNA and proteins to protect populations of the bacteria.

For more than 11 years, researchers Lauren Bakaletz, PhD, and Steve Goodman, PhD, have been working to understand and dismantle biofilms.

"Biofilms are involved in the majority of chronic and recurrent bacterial diseases in the respiratory tract, oral cavity, gastrointestinal tract and urogenital tract," said Dr. Bakaletz, director of the Center for Microbial Pathogenesis and vice president of Basic Sciences at the Abigail Wexner Research Institute at Nationwide Children's (AWRI). "Our work has been to understand the structure and function of biofilms, and ultimately, to find a novel approach to prevent or eradicate them."

Earlier this year, Drs. Bakaletz, Goodman and their team reported in Proceedings of the National Academy of Sciences (PNAS) the role of the DNABII family of bacterial DNA-binding proteins as the "lynchpin" of the biofilm structures.

In their latest paper, published today in EBioMedicine, they demonstrate how using a new platform technology of DNABII-directed antibodies can rapidly disrupt existing biofilms- and prevent them from forming at all.

"This approach attacks a feature common to all biofilms - it's worked on every type of biofilm we've tested," said Dr. Goodman, study author and director of the Oral GI Microbiology Research Affinity Group in the Center for Microbial Pathogenesis at AWRI. "We believe this technology has the potential to resolve infections characterized by communities of heterogenous bacteria where other single-pathogen approaches have failed."

In a preclinical model of otitis media caused by nontypeable Haemophilus inluenzae (NTHI), a monoclonal antibody against a chimeric peptide immunogen designed to target specific regions of the DNABIII proteins, as well as its antigen-binding fragment, was used to disrupt established biofilms. In the preclinical model, this approach resolved the NTHI-induced disease and eradicated the biofilms from the middle ears.

Next, the team used the chimeric peptide immunogen as a preventative immunization, which induced antibodies that prevented biofilm formation and disease development in a viral-bacterial coinfection model.

Finally, the team humanized a monoclonal antibody against the chimeric peptide immunogen, then characterized and validated that it maintained therapeutic efficacy both in vitro and in vivo.

"With this novel approach, we have an opportunity to shift the paradigm for clinical management of a multitude of diseases characterized by recalcitrant biofilms that evade effective intervention today," said Dr. Bakaletz. "Our results from this study are highly supportive of entry into both preventative and therapeutic clinical trials."
The technology described in the study has been licensed to Clarametyx Biosciences, Inc., a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. Drs. Bakaletz and Goodman are co-inventors of the technology and co-chairs of the Clarametyx scientific advisory board.

Nationwide Children's Hospital

Related Proteins Articles from Brightsurf:

New understanding of how proteins operate
A ground-breaking discovery by Centenary Institute scientists has provided new understanding as to the nature of proteins and how they exist and operate in the human body.

Finding a handle to bag the right proteins
A method that lights up tags attached to selected proteins can help to purify the proteins from a mixed protein pool.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

New method to monitor Alzheimer's proteins
IBS-CINAP research team has reported a new method to identify the aggregation state of amyloid beta (Aβ) proteins in solution.

Composing new proteins with artificial intelligence
Scientists have long studied how to improve proteins or design new ones.

Hero proteins are here to save other proteins
Researchers at the University of Tokyo have discovered a new group of proteins, remarkable for their unusual shape and abilities to protect against protein clumps associated with neurodegenerative diseases in lab experiments.

Designer proteins
David Baker, Professor of Biochemistry at the University of Washington to speak at the AAAS 2020 session, 'Synthetic Biology: Digital Design of Living Systems.' Prof.

Gone fishin' -- for proteins
Casting lines into human cells to snag proteins, a team of Montreal researchers has solved a 20-year-old mystery of cell biology.

Coupled proteins
Researchers from Heidelberg University and Sendai University in Japan used new biotechnological methods to study how human cells react to and further process external signals.

Understanding the power of honey through its proteins
Honey is a culinary staple that can be found in kitchens around the world.

Read More: Proteins News and Proteins Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to